<_File frequency="100394"><_A frequency="100394"><_1 frequency="98970"><_Member_State_Concerned frequency="98970" /></_1><_2 frequency="100394"><_EudraCT_number frequency="100394" />
</_2><_3 frequency="100394"><_1 frequency="64050"><_Title_of_the_trial_for_lay_people\,_in_easily_understood\\,_i.e._non-technical,_language frequency="64050" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(bg) frequency="87" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(cs) frequency="823" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(da) frequency="609" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(de) frequency="1259" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(el) frequency="266" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(es) frequency="5774" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(et) frequency="22" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(fi) frequency="275" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(fr) frequency="1177" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(ga) frequency="3" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(hr) frequency="69" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(hu) frequency="684" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(it) frequency="3250" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(lt) frequency="24" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(lv) frequency="9" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(mt) frequency="1" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(nl) frequency="1137" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(pl) frequency="304" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(pt) frequency="118" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(ro) frequency="16" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(sk) frequency="215" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(sl) frequency="62" /><_Title_of_the_trial_for_lay_people,_in_easily_understood,_i.e._non-technical,_language_(sv) frequency="259" /></_1><_2 frequency="50882"><_Name_or_abbreviated_title_of_the_trial_where_available frequency="50882" /><_Name_or_abbreviated_title_of_the_trial_where_available_(bg) frequency="15" /><_Name_or_abbreviated_title_of_the_trial_where_available_(cs) frequency="160" /><_Name_or_abbreviated_title_of_the_trial_where_available_(da) frequency="178" /><_Name_or_abbreviated_title_of_the_trial_where_available_(de) frequency="423" /><_Name_or_abbreviated_title_of_the_trial_where_available_(el) frequency="52" /><_Name_or_abbreviated_title_of_the_trial_where_available_(es) frequency="1650" /><_Name_or_abbreviated_title_of_the_trial_where_available_(et) frequency="4" /><_Name_or_abbreviated_title_of_the_trial_where_available_(fi) frequency="71" /><_Name_or_abbreviated_title_of_the_trial_where_available_(fr) frequency="570" /><_Name_or_abbreviated_title_of_the_trial_where_available_(hr) frequency="15" /><_Name_or_abbreviated_title_of_the_trial_where_available_(hu) frequency="94" /><_Name_or_abbreviated_title_of_the_trial_where_available_(it) frequency="2284" /><_Name_or_abbreviated_title_of_the_trial_where_available_(lt) frequency="10" /><_Name_or_abbreviated_title_of_the_trial_where_available_(lv) frequency="3" /><_Name_or_abbreviated_title_of_the_trial_where_available_(nl) frequency="616" /><_Name_or_abbreviated_title_of_the_trial_where_available_(pl) frequency="100" /><_Name_or_abbreviated_title_of_the_trial_where_available_(pt) frequency="37" /><_Name_or_abbreviated_title_of_the_trial_where_available_(ro) frequency="5" /><_Name_or_abbreviated_title_of_the_trial_where_available_(sk) frequency="24" /><_Name_or_abbreviated_title_of_the_trial_where_available_(sl) frequency="11" /><_Name_or_abbreviated_title_of_the_trial_where_available_(sv) frequency="82" /></_2><_Full_title_of_the_trial frequency="100394" /><_Full_title_of_the_trial_(bg) frequency="195" /><_Full_title_of_the_trial_(cs) frequency="2288" /><_Full_title_of_the_trial_(da) frequency="588" /><_Full_title_of_the_trial_(de) frequency="1584" /><_Full_title_of_the_trial_(el) frequency="332" /><_Full_title_of_the_trial_(es) frequency="5921" /><_Full_title_of_the_trial_(et) frequency="45" /><_Full_title_of_the_trial_(fi) frequency="323" /><_Full_title_of_the_trial_(fr) frequency="1525" /><_Full_title_of_the_trial_(ga) frequency="7" /><_Full_title_of_the_trial_(hr) frequency="159" /><_Full_title_of_the_trial_(hu) frequency="1289" /><_Full_title_of_the_trial_(it) frequency="3605" /><_Full_title_of_the_trial_(lt) frequency="57" /><_Full_title_of_the_trial_(lv) frequency="34" /><_Full_title_of_the_trial_(nl) frequency="1122" /><_Full_title_of_the_trial_(pl) frequency="435" /><_Full_title_of_the_trial_(pt) frequency="143" /><_Full_title_of_the_trial_(ro) frequency="19" /><_Full_title_of_the_trial_(sk) frequency="581" /><_Full_title_of_the_trial_(sl) frequency="124" /><_Full_title_of_the_trial_(sv) frequency="255" /></_3><_4 frequency="100394"><_1 frequency="100394"><_Sponsor's_protocol_code_number frequency="100394" /></_1></_4><_5 frequency="25745"><_1 frequency="6616"><_ISRCTN_(International_Standard_Randomised_Controlled_Trial)_number frequency="6616" /></_1><_2 frequency="13558"><_US_NCT_(ClinicalTrials.gov_registry)_number frequency="13558" /></_2><_3 frequency="3199"><_WHO_Universal_Trial_Reference_Number_(UTRN) frequency="3199" /></_3><_4 frequency="5536"><_Other_Identifiers frequency="5536" /></_4></_5><_7 frequency="100394"><_Trial_is_part_of_a_Paediatric_Investigation_Plan frequency="100394" /></_7><_8 frequency="100394"><_EMA_Decision_number_of_Paediatric_Investigation_Plan frequency="100394" /></_8></_A><_B frequency="100242"><_1 frequency="100242"><_1 frequency="100242"><_Name_of_Sponsor frequency="100242" /></_1><_3 frequency="100242"><_4	Country frequency="100242" /></_3></_1><_3 frequency="100242"><_1 frequency="100242"><_and_B.3.2	Status_of_the_sponsor frequency="100242" /></_1></_3><_4 frequency="100242"><_1 frequency="100242"><_Name_of_organisation_providing_support frequency="100242" /></_1><_2 frequency="100242"><_Country frequency="100242" /></_2><_Source(s)_of_Monetary_or_Material_Support_for_the_clinical_trial frequency="100242" /></_4><_5 frequency="100242"><_1 frequency="100242"><_Name_of_organisation frequency="100242" /></_1><_2 frequency="100242"><_Functional_name_of_contact_point frequency="100242" /></_2><_3 frequency="63031"><_1 frequency="62778"><_Street_Address frequency="62778" /></_1><_2 frequency="62812"><_Town/_city frequency="62812" /></_2><_3 frequency="62306"><_Post_code frequency="62306" /></_3><_4 frequency="62719"><_Country frequency="62719" /></_4></_3><_4 frequency="49419"><_Telephone_number frequency="49419" /></_4><_5 frequency="36454"><_Fax_number frequency="36454" /></_5><_6 frequency="61868"><_E-mail frequency="61868" /></_6></_5></_B><_Clinical_Trial_Type frequency="100394" /><_D frequency="100194"><_1 frequency="100192"><_2 frequency="100192"><_and_D.1.3_IMP_Role frequency="100192" /></_2></_1><_2 frequency="100192"><_1 frequency="100192"><_1 frequency="58402"><_1 frequency="58248"><_Trade_name frequency="58248" /></_1><_2 frequency="57209"><_Name_of_the_Marketing_Authorisation_holder frequency="57209" /></_2></_1><_2 frequency="57895"><_Country_which_granted_the_Marketing_Authorisation frequency="57895" /></_2><_IMP_to_be_used_in_the_trial_has_a_marketing_authorisation frequency="100192" /></_1><_5 frequency="100192"><_1 frequency="100192"><_Orphan_drug_designation_number frequency="100192" /></_1><_The_IMP_has_been_designated_in_this_indication_as_an_orphan_drug_in_the_Community frequency="100192" /></_5></_2><_3 frequency="100192"><_1 frequency="82443"><_Product_name frequency="82443" /></_1><_10 frequency="92206"><_1 frequency="91876"><_Concentration_unit frequency="91876" /></_1><_2 frequency="91156"><_Concentration_type frequency="91156" /></_2><_3 frequency="91718"><_Concentration_number frequency="91718" /></_3></_10><_11 frequency="100192"><_1 frequency="100192"><_Active_substance_of_chemical_origin frequency="100192" /></_1><_10 frequency="100192"><_Medicinal_product_containing_genetically_modified_organisms frequency="100192" /></_10><_11 frequency="100192"><_Herbal_medicinal_product frequency="100192" /></_11><_12 frequency="100192"><_Homeopathic_medicinal_product frequency="100192" /></_12><_13 frequency="100192"><_1 frequency="13485"><_Other_medicinal_product_type frequency="13485" /></_1><_Another_type_of_medicinal_product frequency="100192" /></_13><_2 frequency="100192"><_Active_substance_of_biological/_biotechnological_origin_(other_than_Advanced_Therapy_IMP_(ATIMP) frequency="100192" /></_2><_3 frequency="100192"><_1 frequency="100192"><_Somatic_cell_therapy_medicinal_product frequency="100192" /></_1><_2 frequency="100192"><_Gene_therapy_medical_product frequency="100192" /></_2><_3 frequency="100192"><_Tissue_Engineered_Product frequency="100192" /></_3><_4 frequency="100192"><_Combination_ATIMP_(i.e._one_involving_a_medical_device) frequency="100192" /></_4><_5 frequency="100192"><_1 frequency="475"><_CAT_classification_and_reference_number frequency="475" /></_1><_Committee_on_Advanced_therapies_(CAT)_has_issued_a_classification_for_this_product frequency="100192" /></_5><_Advanced_Therapy_IMP_(ATIMP) frequency="100192" /></_3><_4 frequency="100192"><_Combination_product_that_includes_a_device,_but_does_not_involve_an_Advanced_Therapy frequency="100192" /></_4><_5 frequency="100192"><_Radiopharmaceutical_medicinal_product frequency="100192" /></_5><_6 frequency="100192"><_Immunological_medicinal_product_(such_as_vaccine,_allergen,_immune_serum) frequency="100192" /></_6><_7 frequency="100192"><_Plasma_derived_medicinal_product frequency="100192" /></_7><_8 frequency="100192"><_Extractive_medicinal_product frequency="100192" /></_8><_9 frequency="100192"><_Recombinant_medicinal_product frequency="100192" /></_9></_11><_2 frequency="66377"><_Product_code frequency="66377" /></_2><_4 frequency="100192"><_1 frequency="100192"><_Specific_paediatric_formulation frequency="100192" /></_1><_Pharmaceutical_form frequency="100192" /></_4><_7 frequency="100192"><_Routes_of_administration_for_this_IMP frequency="100192" /></_7><_8 frequency="84772"><_INN_-_Proposed_INN frequency="84772" /></_8><_9 frequency="87663"><_1 frequency="66696"><_CAS_number frequency="66696" /></_1><_2 frequency="62602"><_Current_sponsor_code frequency="62602" /></_2><_3 frequency="55671"><_Other_descriptive_name frequency="55671" /></_3><_4 frequency="46901"><_EV_Substance_Code frequency="46901" /></_4></_9></_3><_8 frequency="49973"><_3 frequency="48530"><_Pharmaceutical_form_of_the_placebo frequency="48530" /></_3><_4 frequency="48617"><_Route_of_administration_of_the_placebo frequency="48617" /></_4><_Placebo frequency="49973" /></_8><_IMP frequency="100192" /></_D><_Date_on_which_this_record_was_first_entered_in_the_EudraCT_database frequency="100394" /><_E frequency="100394"><_1 frequency="100394"><_1 frequency="100394"><_1 frequency="63858"><_Medical_condition_in_easily_understood_language frequency="63858" /><_Medical_condition_in_easily_understood_language_(bg) frequency="49" /><_Medical_condition_in_easily_understood_language_(cs) frequency="209" /><_Medical_condition_in_easily_understood_language_(da) frequency="423" /><_Medical_condition_in_easily_understood_language_(de) frequency="921" /><_Medical_condition_in_easily_understood_language_(el) frequency="241" /><_Medical_condition_in_easily_understood_language_(es) frequency="5828" /><_Medical_condition_in_easily_understood_language_(et) frequency="15" /><_Medical_condition_in_easily_understood_language_(fi) frequency="202" /><_Medical_condition_in_easily_understood_language_(fr) frequency="1053" /><_Medical_condition_in_easily_understood_language_(ga) frequency="2" /><_Medical_condition_in_easily_understood_language_(hr) frequency="48" /><_Medical_condition_in_easily_understood_language_(hu) frequency="294" /><_Medical_condition_in_easily_understood_language_(it) frequency="3203" /><_Medical_condition_in_easily_understood_language_(lt) frequency="18" /><_Medical_condition_in_easily_understood_language_(lv) frequency="7" /><_Medical_condition_in_easily_understood_language_(nl) frequency="913" /><_Medical_condition_in_easily_understood_language_(pl) frequency="225" /><_Medical_condition_in_easily_understood_language_(pt) frequency="82" /><_Medical_condition_in_easily_understood_language_(ro) frequency="11" /><_Medical_condition_in_easily_understood_language_(sk) frequency="49" /><_Medical_condition_in_easily_understood_language_(sl) frequency="38" /><_Medical_condition_in_easily_understood_language_(sv) frequency="214" /></_1><_2 frequency="64531"><_Therapeutic_area frequency="64531" /></_2><_Medical_condition(s)_being_investigated frequency="100394" /><_Medical_condition(s)_being_investigated_(bg) frequency="51" /><_Medical_condition(s)_being_investigated_(cs) frequency="218" /><_Medical_condition(s)_being_investigated_(da) frequency="418" /><_Medical_condition(s)_being_investigated_(de) frequency="899" /><_Medical_condition(s)_being_investigated_(el) frequency="247" /><_Medical_condition(s)_being_investigated_(es) frequency="5887" /><_Medical_condition(s)_being_investigated_(et) frequency="13" /><_Medical_condition(s)_being_investigated_(fi) frequency="199" /><_Medical_condition(s)_being_investigated_(fr) frequency="1156" /><_Medical_condition(s)_being_investigated_(ga) frequency="1" /><_Medical_condition(s)_being_investigated_(hr) frequency="46" /><_Medical_condition(s)_being_investigated_(hu) frequency="289" /><_Medical_condition(s)_being_investigated_(it) frequency="3555" /><_Medical_condition(s)_being_investigated_(lt) frequency="17" /><_Medical_condition(s)_being_investigated_(lv) frequency="5" /><_Medical_condition(s)_being_investigated_(nl) frequency="900" /><_Medical_condition(s)_being_investigated_(pl) frequency="221" /><_Medical_condition(s)_being_investigated_(pt) frequency="81" /><_Medical_condition(s)_being_investigated_(ro) frequency="12" /><_Medical_condition(s)_being_investigated_(sk) frequency="51" /><_Medical_condition(s)_being_investigated_(sl) frequency="38" /><_Medical_condition(s)_being_investigated_(sv) frequency="208" /></_1><_2 frequency="82984"><_Classification_code frequency="82984" /><_Level frequency="82662" /><_MedDRA_version,_system_organ_class,_level,_term_and_classification_code24 frequency="1" /><_Medical_condition_or_disease_under_investigation frequency="82984" /><_System_Organ_Class frequency="58479" /><_Term frequency="78117" /><_Version frequency="82688" /></_2><_3 frequency="100394"><_Condition_being_studied_is_a_rare_disease frequency="100394" /></_3></_1><_1	Cualquier frequency="1"><_enfermedad_(antecedentes_o_presencia_de_enfermedad)_que_contraindique_el_uso_de_anticonceptivos_orales_combinados frequency="1" /></_1	Cualquier><_2 frequency="100394"><_1 frequency="100394"><_Main_objective_of_the_trial frequency="100394" /><_Main_objective_of_the_trial_(bg) frequency="37" /><_Main_objective_of_the_trial_(cs) frequency="130" /><_Main_objective_of_the_trial_(da) frequency="326" /><_Main_objective_of_the_trial_(de) frequency="654" /><_Main_objective_of_the_trial_(el) frequency="244" /><_Main_objective_of_the_trial_(es) frequency="5853" /><_Main_objective_of_the_trial_(et) frequency="9" /><_Main_objective_of_the_trial_(fi) frequency="158" /><_Main_objective_of_the_trial_(fr) frequency="1147" /><_Main_objective_of_the_trial_(ga) frequency="3" /><_Main_objective_of_the_trial_(hr) frequency="38" /><_Main_objective_of_the_trial_(hu) frequency="225" /><_Main_objective_of_the_trial_(it) frequency="3529" /><_Main_objective_of_the_trial_(lt) frequency="15" /><_Main_objective_of_the_trial_(lv) frequency="2" /><_Main_objective_of_the_trial_(nl) frequency="703" /><_Main_objective_of_the_trial_(pl) frequency="203" /><_Main_objective_of_the_trial_(pt) frequency="77" /><_Main_objective_of_the_trial_(ro) frequency="8" /><_Main_objective_of_the_trial_(sk) frequency="32" /><_Main_objective_of_the_trial_(sl) frequency="29" /><_Main_objective_of_the_trial_(sv) frequency="169" /></_1><_2 frequency="100394"><_Secondary_objectives_of_the_trial frequency="100394" /><_Secondary_objectives_of_the_trial_(bg) frequency="35" /><_Secondary_objectives_of_the_trial_(cs) frequency="120" /><_Secondary_objectives_of_the_trial_(da) frequency="285" /><_Secondary_objectives_of_the_trial_(de) frequency="599" /><_Secondary_objectives_of_the_trial_(el) frequency="228" /><_Secondary_objectives_of_the_trial_(es) frequency="5782" /><_Secondary_objectives_of_the_trial_(et) frequency="8" /><_Secondary_objectives_of_the_trial_(fi) frequency="131" /><_Secondary_objectives_of_the_trial_(fr) frequency="1126" /><_Secondary_objectives_of_the_trial_(ga) frequency="4" /><_Secondary_objectives_of_the_trial_(hr) frequency="38" /><_Secondary_objectives_of_the_trial_(hu) frequency="202" /><_Secondary_objectives_of_the_trial_(it) frequency="3498" /><_Secondary_objectives_of_the_trial_(lt) frequency="16" /><_Secondary_objectives_of_the_trial_(lv) frequency="2" /><_Secondary_objectives_of_the_trial_(nl) frequency="666" /><_Secondary_objectives_of_the_trial_(pl) frequency="203" /><_Secondary_objectives_of_the_trial_(pt) frequency="71" /><_Secondary_objectives_of_the_trial_(ro) frequency="8" /><_Secondary_objectives_of_the_trial_(sk) frequency="30" /><_Secondary_objectives_of_the_trial_(sl) frequency="25" /><_Secondary_objectives_of_the_trial_(sv) frequency="168" /></_2><_2	Secondary frequency="1"><_objectives frequency="1" /></_2	Secondary><_3 frequency="100393"><_1 frequency="13818"><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives frequency="13818" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(bg) frequency="6" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(cs) frequency="19" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(da) frequency="23" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(de) frequency="57" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(el) frequency="31" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(es) frequency="832" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(fi) frequency="6" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(fr) frequency="95" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(ga) frequency="1" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(hr) frequency="4" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(hu) frequency="16" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(it) frequency="524" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(lt) frequency="1" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(nl) frequency="39" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(pl) frequency="33" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(pt) frequency="9" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(ro) frequency="2" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(sk) frequency="9" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(sl) frequency="2" /><_Full_title,_date_and_version_of_each_sub-study_and_their_related_objectives_(sv) frequency="13" /></_1><_Trial_contains_a_sub-study frequency="100393" /></_3></_2><_3 frequency="100393"><_Criteri_di_inclusione_principali_(elencare_i_pi&#249;_importanti) frequency="1" /><_Criteri_di_inclusione_principali(elencare_i_pi&#249;_importanti) frequency="1" /><_Principal_inclusion_criteria frequency="100393" /><_Principal_inclusion_criteria_(bg) frequency="33" /><_Principal_inclusion_criteria_(cs) frequency="111" /><_Principal_inclusion_criteria_(da) frequency="313" /><_Principal_inclusion_criteria_(de) frequency="599" /><_Principal_inclusion_criteria_(el) frequency="241" /><_Principal_inclusion_criteria_(es) frequency="5843" /><_Principal_inclusion_criteria_(et) frequency="9" /><_Principal_inclusion_criteria_(fi) frequency="146" /><_Principal_inclusion_criteria_(fr) frequency="1104" /><_Principal_inclusion_criteria_(ga) frequency="1" /><_Principal_inclusion_criteria_(hr) frequency="39" /><_Principal_inclusion_criteria_(hu) frequency="207" /><_Principal_inclusion_criteria_(it) frequency="3474" /><_Principal_inclusion_criteria_(lt) frequency="16" /><_Principal_inclusion_criteria_(lv) frequency="2" /><_Principal_inclusion_criteria_(nl) frequency="673" /><_Principal_inclusion_criteria_(pl) frequency="199" /><_Principal_inclusion_criteria_(pt) frequency="64" /><_Principal_inclusion_criteria_(ro) frequency="8" /><_Principal_inclusion_criteria_(sk) frequency="30" /><_Principal_inclusion_criteria_(sl) frequency="24" /><_Principal_inclusion_criteria_(sv) frequency="156" /></_3><_4 frequency="100367"><_Criteri_di_esclusione_principali(elencare_i_pi&#249;_importanti) frequency="1" /><_Principal_exclusion_criteria frequency="100367" /><_Principal_exclusion_criteria_(bg) frequency="33" /><_Principal_exclusion_criteria_(cs) frequency="112" /><_Principal_exclusion_criteria_(da) frequency="310" /><_Principal_exclusion_criteria_(de) frequency="595" /><_Principal_exclusion_criteria_(el) frequency="241" /><_Principal_exclusion_criteria_(es) frequency="5831" /><_Principal_exclusion_criteria_(et) frequency="10" /><_Principal_exclusion_criteria_(fi) frequency="143" /><_Principal_exclusion_criteria_(fr) frequency="1105" /><_Principal_exclusion_criteria_(ga) frequency="5" /><_Principal_exclusion_criteria_(hr) frequency="39" /><_Principal_exclusion_criteria_(hu) frequency="193" /><_Principal_exclusion_criteria_(it) frequency="3473" /><_Principal_exclusion_criteria_(lt) frequency="16" /><_Principal_exclusion_criteria_(lv) frequency="1" /><_Principal_exclusion_criteria_(nl) frequency="662" /><_Principal_exclusion_criteria_(pl) frequency="200" /><_Principal_exclusion_criteria_(pt) frequency="63" /><_Principal_exclusion_criteria_(ro) frequency="8" /><_Principal_exclusion_criteria_(sk) frequency="30" /><_Principal_exclusion_criteria_(sl) frequency="26" /><_Principal_exclusion_criteria_(sv) frequency="156" /></_4><_5 frequency="100352"><_1 frequency="100352"><_1 frequency="63929"><_Tempo/i_di_rilevazione_di_questo_end_point frequency="3" /><_Timepoint(s)_of_evaluation_of_this_end_point frequency="63928" /><_Timepoint(s)_of_evaluation_of_this_end_point_(bg) frequency="35" /><_Timepoint(s)_of_evaluation_of_this_end_point_(cs) frequency="105" /><_Timepoint(s)_of_evaluation_of_this_end_point_(da) frequency="289" /><_Timepoint(s)_of_evaluation_of_this_end_point_(de) frequency="559" /><_Timepoint(s)_of_evaluation_of_this_end_point_(el) frequency="235" /><_Timepoint(s)_of_evaluation_of_this_end_point_(es) frequency="5788" /><_Timepoint(s)_of_evaluation_of_this_end_point_(et) frequency="11" /><_Timepoint(s)_of_evaluation_of_this_end_point_(fi) frequency="121" /><_Timepoint(s)_of_evaluation_of_this_end_point_(fr) frequency="946" /><_Timepoint(s)_of_evaluation_of_this_end_point_(ga) frequency="1" /><_Timepoint(s)_of_evaluation_of_this_end_point_(hr) frequency="38" /><_Timepoint(s)_of_evaluation_of_this_end_point_(hu) frequency="160" /><_Timepoint(s)_of_evaluation_of_this_end_point_(it) frequency="3138" /><_Timepoint(s)_of_evaluation_of_this_end_point_(lt) frequency="14" /><_Timepoint(s)_of_evaluation_of_this_end_point_(lv) frequency="2" /><_Timepoint(s)_of_evaluation_of_this_end_point_(nl) frequency="637" /><_Timepoint(s)_of_evaluation_of_this_end_point_(pl) frequency="194" /><_Timepoint(s)_of_evaluation_of_this_end_point_(pt) frequency="63" /><_Timepoint(s)_of_evaluation_of_this_end_point_(ro) frequency="9" /><_Timepoint(s)_of_evaluation_of_this_end_point_(sk) frequency="28" /><_Timepoint(s)_of_evaluation_of_this_end_point_(sl) frequency="26" /><_Timepoint(s)_of_evaluation_of_this_end_point_(sv) frequency="147" /><_Timepoint(s)_of_evaluation_of_this_endpoint frequency="1" /></_1><_End_point_primario_(ripetere_se_necessario) frequency="1" /><_End_point_secondario_(ripetere_se_necessario) frequency="1" /><_Primary_End_Point_(repeat_as_necessary)25 frequency="1" /><_Primary_end_point(s) frequency="100352" /><_Primary_end_point(s)_(bg) frequency="34" /><_Primary_end_point(s)_(cs) frequency="110" /><_Primary_end_point(s)_(da) frequency="297" /><_Primary_end_point(s)_(de) frequency="583" /><_Primary_end_point(s)_(el) frequency="241" /><_Primary_end_point(s)_(es) frequency="5837" /><_Primary_end_point(s)_(et) frequency="10" /><_Primary_end_point(s)_(fi) frequency="124" /><_Primary_end_point(s)_(fr) frequency="1079" /><_Primary_end_point(s)_(ga) frequency="1" /><_Primary_end_point(s)_(hr) frequency="39" /><_Primary_end_point(s)_(hu) frequency="178" /><_Primary_end_point(s)_(it) frequency="3467" /><_Primary_end_point(s)_(lt) frequency="14" /><_Primary_end_point(s)_(lv) frequency="1" /><_Primary_end_point(s)_(nl) frequency="646" /><_Primary_end_point(s)_(pl) frequency="201" /><_Primary_end_point(s)_(pt) frequency="65" /><_Primary_end_point(s)_(ro) frequency="9" /><_Primary_end_point(s)_(sk) frequency="30" /><_Primary_end_point(s)_(sl) frequency="26" /><_Primary_end_point(s)_(sv) frequency="158" /></_1><_2 frequency="63991"><_1 frequency="63561"><_Timepoint(s)_of_evaluation_of_this_end_point frequency="63560" /><_Timepoint(s)_of_evaluation_of_this_end_point_(bg) frequency="35" /><_Timepoint(s)_of_evaluation_of_this_end_point_(cs) frequency="103" /><_Timepoint(s)_of_evaluation_of_this_end_point_(da) frequency="281" /><_Timepoint(s)_of_evaluation_of_this_end_point_(de) frequency="531" /><_Timepoint(s)_of_evaluation_of_this_end_point_(el) frequency="230" /><_Timepoint(s)_of_evaluation_of_this_end_point_(es) frequency="5727" /><_Timepoint(s)_of_evaluation_of_this_end_point_(et) frequency="10" /><_Timepoint(s)_of_evaluation_of_this_end_point_(fi) frequency="111" /><_Timepoint(s)_of_evaluation_of_this_end_point_(fr) frequency="894" /><_Timepoint(s)_of_evaluation_of_this_end_point_(ga) frequency="3" /><_Timepoint(s)_of_evaluation_of_this_end_point_(hr) frequency="38" /><_Timepoint(s)_of_evaluation_of_this_end_point_(hu) frequency="135" /><_Timepoint(s)_of_evaluation_of_this_end_point_(it) frequency="3113" /><_Timepoint(s)_of_evaluation_of_this_end_point_(lt) frequency="13" /><_Timepoint(s)_of_evaluation_of_this_end_point_(lv) frequency="2" /><_Timepoint(s)_of_evaluation_of_this_end_point_(nl) frequency="627" /><_Timepoint(s)_of_evaluation_of_this_end_point_(pl) frequency="193" /><_Timepoint(s)_of_evaluation_of_this_end_point_(pt) frequency="60" /><_Timepoint(s)_of_evaluation_of_this_end_point_(ro) frequency="9" /><_Timepoint(s)_of_evaluation_of_this_end_point_(sk) frequency="28" /><_Timepoint(s)_of_evaluation_of_this_end_point_(sl) frequency="23" /><_Timepoint(s)_of_evaluation_of_this_end_point_(sv) frequency="145" /><_Timepoint(s)_of_evaluation_of_this_endpoint frequency="1" /></_1><_End_point_secondario_(ripetere_se_necessario) frequency="1" /><_Secondary_End_Point_(repeat_as_necessary) frequency="1" /><_Secondary_end_point(s) frequency="63975" /><_Secondary_end_point(s)_(bg) frequency="33" /><_Secondary_end_point(s)_(cs) frequency="105" /><_Secondary_end_point(s)_(da) frequency="286" /><_Secondary_end_point(s)_(de) frequency="550" /><_Secondary_end_point(s)_(el) frequency="234" /><_Secondary_end_point(s)_(es) frequency="5776" /><_Secondary_end_point(s)_(et) frequency="8" /><_Secondary_end_point(s)_(fi) frequency="114" /><_Secondary_end_point(s)_(fr) frequency="967" /><_Secondary_end_point(s)_(ga) frequency="1" /><_Secondary_end_point(s)_(hr) frequency="39" /><_Secondary_end_point(s)_(hu) frequency="155" /><_Secondary_end_point(s)_(it) frequency="3126" /><_Secondary_end_point(s)_(lt) frequency="14" /><_Secondary_end_point(s)_(lv) frequency="1" /><_Secondary_end_point(s)_(nl) frequency="636" /><_Secondary_end_point(s)_(pl) frequency="197" /><_Secondary_end_point(s)_(pt) frequency="62" /><_Secondary_end_point(s)_(ro) frequency="9" /><_Secondary_end_point(s)_(sk) frequency="30" /><_Secondary_end_point(s)_(sl) frequency="22" /><_Secondary_end_point(s)_(sv) frequency="150" /></_2><_END_POINT(S) frequency="2" /></_5><_6 frequency="100349"><_1 frequency="100349"><_Diagnosis frequency="100349" /></_1><_10 frequency="100349"><_Pharmacogenetic frequency="100349" /></_10><_11 frequency="100349"><_Pharmacogenomic frequency="100349" /></_11><_12 frequency="100349"><_Pharmacoeconomic frequency="100349" /></_12><_13 frequency="100349"><_1 frequency="18779"><_Other_scope_of_the_trial_description frequency="18779" /><_Other_scope_of_the_trial_description_(bg) frequency="1" /><_Other_scope_of_the_trial_description_(cs) frequency="16" /><_Other_scope_of_the_trial_description_(da) frequency="31" /><_Other_scope_of_the_trial_description_(de) frequency="47" /><_Other_scope_of_the_trial_description_(el) frequency="30" /><_Other_scope_of_the_trial_description_(es) frequency="999" /><_Other_scope_of_the_trial_description_(fi) frequency="10" /><_Other_scope_of_the_trial_description_(fr) frequency="114" /><_Other_scope_of_the_trial_description_(hr) frequency="11" /><_Other_scope_of_the_trial_description_(hu) frequency="11" /><_Other_scope_of_the_trial_description_(it) frequency="599" /><_Other_scope_of_the_trial_description_(lt) frequency="1" /><_Other_scope_of_the_trial_description_(mt) frequency="1" /><_Other_scope_of_the_trial_description_(nl) frequency="80" /><_Other_scope_of_the_trial_description_(pl) frequency="21" /><_Other_scope_of_the_trial_description_(pt) frequency="10" /><_Other_scope_of_the_trial_description_(ro) frequency="2" /><_Other_scope_of_the_trial_description_(sk) frequency="6" /><_Other_scope_of_the_trial_description_(sl) frequency="3" /><_Other_scope_of_the_trial_description_(sv) frequency="31" /></_1><_Others frequency="100349" /></_13><_2 frequency="100349"><_Prophylaxis frequency="100349" /></_2><_3 frequency="100349"><_Therapy frequency="100349" /></_3><_4 frequency="100349"><_Safety frequency="100349" /></_4><_5 frequency="100349"><_Efficacy frequency="100349" /></_5><_6 frequency="100349"><_Pharmacokinetic frequency="100349" /></_6><_7 frequency="100349"><_Pharmacodynamic frequency="100349" /></_7><_8 frequency="100349"><_Bioequivalence frequency="100349" /></_8><_9 frequency="100349"><_Dose_response frequency="100349" /></_9></_6><_7 frequency="100349"><_1 frequency="100349"><_1 frequency="100349"><_First_administration_to_humans frequency="100349" /></_1><_2 frequency="100349"><_Bioequivalence_study frequency="100349" /></_2><_3 frequency="100349"><_1 frequency="100349"><_Other_trial_type_description frequency="100349" /><_Other_trial_type_description_(bg) frequency="1" /><_Other_trial_type_description_(cs) frequency="3" /><_Other_trial_type_description_(da) frequency="7" /><_Other_trial_type_description_(de) frequency="17" /><_Other_trial_type_description_(el) frequency="5" /><_Other_trial_type_description_(es) frequency="227" /><_Other_trial_type_description_(fr) frequency="24" /><_Other_trial_type_description_(hu) frequency="2" /><_Other_trial_type_description_(it) frequency="100" /><_Other_trial_type_description_(nl) frequency="19" /><_Other_trial_type_description_(pl) frequency="8" /><_Other_trial_type_description_(sv) frequency="2" /></_1><_Other frequency="100349" /></_3><_Human_pharmacology_(Phase_I) frequency="100349" /></_1><_2 frequency="100349"><_Therapeutic_exploratory_(Phase_II) frequency="100349" /></_2><_3 frequency="100349"><_Therapeutic_confirmatory_(Phase_III) frequency="100349" /></_3><_4 frequency="100349"><_Therapeutic_use_(Phase_IV) frequency="100349" /></_4></_7><_8 frequency="100349"><_1 frequency="100349"><_1 frequency="100349"><_Randomised frequency="100349" /></_1><_2 frequency="100349"><_Open frequency="100349" /></_2><_3 frequency="100349"><_Single_blind frequency="100349" /></_3><_4 frequency="100349"><_Double_blind frequency="100349" /></_4><_5 frequency="100349"><_Parallel_group frequency="100349" /></_5><_6 frequency="100349"><_Cross_over frequency="100349" /></_6><_7 frequency="100349"><_1 frequency="12826"><_Other_trial_design_description frequency="12826" /><_Other_trial_design_description_(bg) frequency="6" /><_Other_trial_design_description_(cs) frequency="7" /><_Other_trial_design_description_(da) frequency="21" /><_Other_trial_design_description_(de) frequency="59" /><_Other_trial_design_description_(el) frequency="21" /><_Other_trial_design_description_(es) frequency="464" /><_Other_trial_design_description_(et) frequency="1" /><_Other_trial_design_description_(fi) frequency="11" /><_Other_trial_design_description_(fr) frequency="64" /><_Other_trial_design_description_(ga) frequency="1" /><_Other_trial_design_description_(hr) frequency="4" /><_Other_trial_design_description_(hu) frequency="17" /><_Other_trial_design_description_(it) frequency="440" /><_Other_trial_design_description_(lt) frequency="5" /><_Other_trial_design_description_(lv) frequency="1" /><_Other_trial_design_description_(nl) frequency="65" /><_Other_trial_design_description_(pl) frequency="21" /><_Other_trial_design_description_(pt) frequency="5" /><_Other_trial_design_description_(sk) frequency="2" /><_Other_trial_design_description_(sl) frequency="2" /><_Other_trial_design_description_(sv) frequency="14" /></_1><_Other frequency="100349" /></_7><_Controlled frequency="100349" /></_1><_2 frequency="100349"><_1 frequency="100349"><_Other_medicinal_product(s) frequency="100349" /></_1><_2 frequency="100349"><_Placebo frequency="100349" /></_2><_3 frequency="100349"><_1 frequency="13955"><_Comparator_description frequency="13955" /><_Comparator_description_(bg) frequency="2" /><_Comparator_description_(cs) frequency="17" /><_Comparator_description_(da) frequency="53" /><_Comparator_description_(de) frequency="129" /><_Comparator_description_(el) frequency="29" /><_Comparator_description_(es) frequency="643" /><_Comparator_description_(et) frequency="2" /><_Comparator_description_(fi) frequency="37" /><_Comparator_description_(fr) frequency="130" /><_Comparator_description_(hr) frequency="5" /><_Comparator_description_(hu) frequency="8" /><_Comparator_description_(it) frequency="648" /><_Comparator_description_(lt) frequency="9" /><_Comparator_description_(lv) frequency="1" /><_Comparator_description_(nl) frequency="159" /><_Comparator_description_(pl) frequency="24" /><_Comparator_description_(pt) frequency="10" /><_Comparator_description_(sk) frequency="4" /><_Comparator_description_(sl) frequency="3" /><_Comparator_description_(sv) frequency="30" /></_1><_Other frequency="100349" /></_3><_4 frequency="56490"><_Number_of_treatment_arms_in_the_trial frequency="56490" /></_4></_2><_3 frequency="100349"><_The_trial_involves_single_site_in_the_Member_State_concerned frequency="98925" /><_Will_this_trial_be_conducted_at_a_single_site_globally? frequency="1424" /></_3><_4 frequency="100349"><_1 frequency="72633"><_Number_of_sites_anticipated_in_Member_State_concerned frequency="72633" /></_1><_The_trial_involves_multiple_sites_in_the_Member_State_concerned frequency="98925" /><_Will_this_trial_be_conducted_at_multiple_sites_globally? frequency="1424" /></_4><_5 frequency="98925"><_1 frequency="70492"><_Number_of_sites_anticipated_in_the_EEA frequency="70492" /></_1><_The_trial_involves_multiple_Member_States frequency="98925" /></_5><_6 frequency="100349"><_1 frequency="98925"><_Trial_being_conducted_both_within_and_outside_the_EEA frequency="98925" /></_1><_2 frequency="100349"><_Trial_being_conducted_completely_outside_of_the_EEA frequency="100349" /></_2><_3 frequency="69223"><_If_E.8.6.1_or_E.8.6.2_are_Yes,_specify_the_regions_in_which_trial_sites_are_planned frequency="67799" /><_Specify_the_countries_outside_of_the_EEA_in_which_trial_sites_are_planned frequency="1424" /></_3></_6><_7 frequency="100349"><_Trial_has_a_data_monitoring_committee frequency="100349" /></_7><_8 frequency="100349"><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial frequency="100349" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(bg) frequency="39" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(cs) frequency="100" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(da) frequency="243" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(de) frequency="461" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(el) frequency="170" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(es) frequency="5076" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(et) frequency="8" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(fi) frequency="94" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(fr) frequency="726" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(ga) frequency="2" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(hr) frequency="41" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(hu) frequency="129" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(it) frequency="3204" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(lt) frequency="12" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(lv) frequency="5" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(nl) frequency="587" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(pl) frequency="188" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(pt) frequency="57" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(ro) frequency="8" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(sk) frequency="24" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(sl) frequency="24" /><_Definition_of_the_end_of_the_trial_and_justification_where_it_is_not_the_last_visit_of_the_last_subject_undergoing_the_trial_(sv) frequency="147" /></_8><_9 frequency="100346"><_1 frequency="98925"><_In_the_Member_State_concerned_days frequency="98925" /><_In_the_Member_State_concerned_months frequency="98925" /><_In_the_Member_State_concerned_years frequency="98925" /></_1><_2 frequency="87325"><_In_all_countries_concerned_by_the_trial_days frequency="53123" /><_In_all_countries_concerned_by_the_trial_months frequency="79412" /><_In_all_countries_concerned_by_the_trial_years frequency="80802" /></_2></_9><_Any_of_the_following_medical_conditions_despite_adequate_therapeutic_management frequency="1" /></_8><_Any frequency="3"><_3_of_the_following_9_criteria frequency="3" /></_Any><_Comparar frequency="1"><_la_frecuencia,_temporalidad,_y_causas_de_no_completar_el_tratamiento_entre_la_rama_TDO_y_las_AA_(combinadas_y_por_separado)_incluyendo_la_interrupci&#243;n_por frequency="1" /></_Comparar><_Granulosa frequency="1"><_cell_tumours_and_other_sex_cord_stromal_tumours frequency="1" /></_Granulosa><_Indicadores frequency="1"><_de_funci&#243;n_cerebral frequency="1" /></_Indicadores><_Occurrence frequency="1"><_of_potential_Immune-Mediated_Diseases_(pIMDs) frequency="1" /></_Occurrence><_Octreotida frequency="1"><_LAR,_Pasireotida_LAR_y_Lanreotida_Autogel&#174; frequency="1" /></_Octreotida><_Other_investigator_on-site_qualitative_assessments_at_each_scheduled_post-baseline_visit frequency="4" /><_Paciente_que_reciban_tratamiento_est&#225;ndar_para_la_prevenci&#243;n_de_recurrencia_hemorr&#225;gica frequency="1" /><_Param&#232;tres_de_coagulation frequency="1" /><_Revesz_syndrome frequency="1" /><_Safety_and_tolerability frequency="1" /><_To frequency="1"><_compare_the_frequency,_timing,_and_causes_for_failure_to_complete_treatment_between_the_DOT_arm_and_the_SAT_arms_(combined_and_individually)_including_discontinuation_due_to frequency="1" /></_To><_risico_gedrag frequency="1" /></_E><_EudraCT_Number frequency="100394" /><_F frequency="100392"><_- frequency="1"><_Pacientes_con_3_de_cualquiera_de_los_siguientes_7_factores_de_riesgo frequency="1" /></_-><_1 frequency="100381"><_1 frequency="100381"><_1 frequency="100381"><_1 frequency="4416"><_Number_of_subjects_for_this_age_range frequency="4416" /></_1><_In_Utero frequency="100381" /></_1><_2 frequency="100381"><_1 frequency="4913"><_Number_of_subjects_for_this_age_range frequency="4913" /></_1><_Preterm_newborn_infants_(up_to_gestational_age_<_37_weeks) frequency="100381" /></_2><_3 frequency="100381"><_1 frequency="5353"><_Number_of_subjects_for_this_age_range frequency="5353" /></_1><_Newborns_(0-27_days) frequency="100381" /></_3><_4 frequency="100381"><_1 frequency="7943"><_Number_of_subjects_for_this_age_range frequency="7943" /></_1><_Infants_and_toddlers_(28_days-23_months) frequency="100381" /></_4><_5 frequency="100381"><_1 frequency="11274"><_Number_of_subjects_for_this_age_range frequency="11274" /></_1><_Children_(2-11years) frequency="100381" /></_5><_6 frequency="100381"><_1 frequency="13448"><_Number_of_subjects_for_this_age_range frequency="13448" /></_1><_Adolescents_(12-17_years) frequency="100381" /></_6><_Number_of_subjects_for_this_age_range frequency="17957" /><_Trial_has_subjects_under_18 frequency="100381" /></_1><_2 frequency="100381"><_1 frequency="56673"><_Number_of_subjects_for_this_age_range frequency="56673" /></_1><_Adults_(18-64_years) frequency="100381" /></_2><_3 frequency="100381"><_1 frequency="49031"><_Number_of_subjects_for_this_age_range frequency="49031" /></_1><_Elderly_(>=65_years) frequency="100381" /></_3></_1><_2 frequency="100381"><_1 frequency="100381"><_Female frequency="100381" /></_1><_2 frequency="100381"><_Male frequency="100381" /></_2></_2><_3 frequency="100381"><_1 frequency="100381"><_Healthy_volunteers frequency="100381" /></_1><_2 frequency="100381"><_Patients frequency="100381" /></_2><_3 frequency="100381"><_1 frequency="86979"><_Women_of_childbearing_potential_not_using_contraception frequency="86979" /></_1><_2 frequency="100381"><_Women_of_child-bearing_potential_using_contraception frequency="100381" /></_2><_3 frequency="100381"><_Pregnant_women frequency="100381" /></_3><_4 frequency="100381"><_Nursing_women frequency="100381" /></_4><_5 frequency="100381"><_Emergency_situation frequency="100381" /></_5><_6 frequency="100381"><_1 frequency="13605"><_Details_of_subjects_incapable_of_giving_consent frequency="13605" /><_Details_of_subjects_incapable_of_giving_consent_(bg) frequency="4" /><_Details_of_subjects_incapable_of_giving_consent_(cs) frequency="16" /><_Details_of_subjects_incapable_of_giving_consent_(da) frequency="34" /><_Details_of_subjects_incapable_of_giving_consent_(de) frequency="75" /><_Details_of_subjects_incapable_of_giving_consent_(el) frequency="35" /><_Details_of_subjects_incapable_of_giving_consent_(es) frequency="579" /><_Details_of_subjects_incapable_of_giving_consent_(et) frequency="6" /><_Details_of_subjects_incapable_of_giving_consent_(fi) frequency="23" /><_Details_of_subjects_incapable_of_giving_consent_(fr) frequency="110" /><_Details_of_subjects_incapable_of_giving_consent_(hr) frequency="2" /><_Details_of_subjects_incapable_of_giving_consent_(hu) frequency="17" /><_Details_of_subjects_incapable_of_giving_consent_(it) frequency="434" /><_Details_of_subjects_incapable_of_giving_consent_(lt) frequency="4" /><_Details_of_subjects_incapable_of_giving_consent_(nl) frequency="86" /><_Details_of_subjects_incapable_of_giving_consent_(pl) frequency="33" /><_Details_of_subjects_incapable_of_giving_consent_(pt) frequency="9" /><_Details_of_subjects_incapable_of_giving_consent_(sk) frequency="5" /><_Details_of_subjects_incapable_of_giving_consent_(sl) frequency="2" /><_Details_of_subjects_incapable_of_giving_consent_(sv) frequency="20" /></_1><_Subjects_incapable_of_giving_consent_personally frequency="100381" /></_6><_7 frequency="100381"><_1 frequency="2240"><_Details_of_other_specific_vulnerable_populations frequency="2240" /><_Details_of_other_specific_vulnerable_populations_(cs) frequency="1" /><_Details_of_other_specific_vulnerable_populations_(da) frequency="12" /><_Details_of_other_specific_vulnerable_populations_(de) frequency="7" /><_Details_of_other_specific_vulnerable_populations_(el) frequency="2" /><_Details_of_other_specific_vulnerable_populations_(es) frequency="89" /><_Details_of_other_specific_vulnerable_populations_(et) frequency="1" /><_Details_of_other_specific_vulnerable_populations_(fi) frequency="2" /><_Details_of_other_specific_vulnerable_populations_(fr) frequency="15" /><_Details_of_other_specific_vulnerable_populations_(hu) frequency="2" /><_Details_of_other_specific_vulnerable_populations_(it) frequency="78" /><_Details_of_other_specific_vulnerable_populations_(lt) frequency="1" /><_Details_of_other_specific_vulnerable_populations_(nl) frequency="27" /><_Details_of_other_specific_vulnerable_populations_(pl) frequency="2" /><_Details_of_other_specific_vulnerable_populations_(sk) frequency="1" /><_Details_of_other_specific_vulnerable_populations_(sl) frequency="1" /><_Details_of_other_specific_vulnerable_populations_(sv) frequency="7" /></_1><_Others frequency="100381" /></_7><_Specific_vulnerable_populations frequency="100381" /></_3></_3><_4 frequency="100381"><_1 frequency="98957"><_In_the_member_state frequency="98957" /></_1><_2 frequency="86056"><_1 frequency="81614"><_In_the_EEA frequency="81614" /></_1><_2 frequency="85407"><_In_the_whole_clinical_trial frequency="85407" /></_2></_2></_4><_5 frequency="77415"><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition) frequency="77415" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(bg) frequency="25" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(cs) frequency="75" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(da) frequency="241" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(de) frequency="495" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(el) frequency="166" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(es) frequency="4572" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(et) frequency="8" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(fi) frequency="91" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(fr) frequency="572" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(hr) frequency="32" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(hu) frequency="84" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(it) frequency="3080" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(lt) frequency="13" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(lv) frequency="1" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(mt) frequency="1" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(nl) frequency="604" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(pl) frequency="159" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(pt) frequency="53" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(ro) frequency="7" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(sk) frequency="14" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(sl) frequency="19" /><_Plans_for_treatment_or_care_after_the_subject_has_ended_the_participation_in_the_trial_(if_it_is_different_from_the_expected_normal_treatment_of_that_condition)_(sv) frequency="141" /></_5><_Any_lymphocyte-depleting_therapies,_including,_but_not_limited_to frequency="5" /><_For frequency="1"><_HIV-positive_individuals,_CD4_T_cell_count_greater_than_or_equal_to_100_cells/mm3_based_on_testing_performed_at_or_within_30_days_prior_to_study_entry.__HIV-positive_individuals_will_be_enrolled_in_a_staged_approach_as_described_in_Section_8.3.10.1,_specifically frequency="1" /></_For><_Indicadores frequency="1"><_de_lesi&#243;n_estructural_del_SNC frequency="1" /></_Indicadores><_Mitotano frequency="1" /><_Pharmacokinetic_assay_(for_argatroban_treatment_arms) frequency="2" /><_SOA frequency="1" /><_&#246; frequency="1"><_&#228;r_urvalskriterier_samma_f&#246;r_alla_tre_grupper frequency="1" /></_&#246;></_F><_G frequency="7608"><_4 frequency="7604"><_1 frequency="3659"><_Name_of_Organisation frequency="3659" /></_1><_3 frequency="3160"><_4 frequency="3160"><_Network_Country frequency="3160" /></_4></_3><_Investigator_Network_to_be_involved_in_the_Trial frequency="7604" /></_4><_Anti-heparin/PF4_antibody_assay frequency="2" /><_Any_immunosuppressive_agents,_including,_but_not_limited_to frequency="5" /><_Cualquier frequency="1"><_f&#225;rmaco_inmunodepresor,_incluidos,_entre_otros frequency="1" /></_Cualquier><_Farmacocin&#233;tica frequency="1" /><_Keuze frequency="1" /><_Laboratory frequency="1"><_parameters_done_at_or_within_14_days_prior_to_screening frequency="1" /></_Laboratory><_Otra frequency="1"><_terapia_experimental frequency="1" /></_Otra></_G><_Link frequency="100394" /><_N frequency="98970"><_B frequency="31"><_1 frequency="1" /><_2 frequency="1" /><_Contraindication_to_the_administration_of_the_DTPa-HBV-IPV/Hib_vaccine_does_not_constitute_contraindication_to_the_administration_of_the_pneumococcal_vaccine._Children_who_will_not_receive_the_DTPa-HBV-IPV/Hib_vaccine_may_still_receive_the_study_pneumococcal_vaccine frequency="3" /><_Females frequency="1"><_of_non-childbearing_or_childbearing_potential_may_be_enrolled._It_is_not_contraindicated_to_enrol_females_of_childbearing_potential,_however,_they_must_have_a_a_negative_pregnancy_test_at_study_entry_and_must_have_practiced_adequate_contraception_for_at_least_30_days_prior_to_study_entry._Additionally,_the_subject_agrees_to_one_of_the_methods_listed_in_the_protocol_for_avoidance_of_pregnancy_during_the_entire_study_treatment_period frequency="1" /></_Females><_Females_of_non-childbearing_or_childbearing_potential_may_be_enrolled._Females_of_childbearing_potential_must_have_a_negative_pregnancy_test_at_study_entry_and_must_have_practiced_adequate_contraception_for_at_least_30_days_prior_to_study_entry._Additionally,_the_subject_agrees_to_one_of_the_following_methods_for_avoidance_of_pregnancy_during_the_entire_study_treatment_period frequency="1" /><_Females_of_non-childbearing_or_childbearing_potential_may_be_enrolled._It_is_not_contraindicated_to_enrol_females_of_childbearing_potential;_however,_they_must_have_a_negative_pregnancy_test_at_study_entry_and_must_have_practiced_adequate_contraception_for_at_least_30_days_prior_to_study_entry._Additionally,_the_subject_agrees_to_one_of_the_methods_listed_in_the_protocol_for_avoidance_of_pregnancy_during_the_entire_study_treatment_period frequency="1" /></_B><_Competent_Authority_Decision frequency="98970" /><_Date_of_Competent_Authority_Decision frequency="98970" /><_Date_of_Ethics_Committee_Opinion frequency="98970" /><_Ethics_Committee_Opinion frequency="98970" /><_Ethics_Committee_Opinion_of_the_trial_application frequency="98970" /><_meningitidis_infection frequency="1" /></_N><_National_Competent_Authority frequency="98970" /><_P frequency="98970"><_Date_of_the_global_end_of_the_trial frequency="49272" /><_End_of_Trial_Status frequency="98970" /></_P><_Sponsor's_Protocol_Code_Number frequency="100394" /><_Trial_Status frequency="98970" /></_File>